Relay Therapeutics Files 8-K

Ticker: RLAY · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1812364

Relay Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyRelay Therapeutics, Inc. (RLAY)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, disclosure

TL;DR

Relay Therapeutics filed an 8-K on Jan 13, 2025. Check for updates.

AI Summary

On January 13, 2025, Relay Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Relay Therapeutics is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific financial or operational details that would indicate a change in risk.

Key Players & Entities

  • Relay Therapeutics, Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of earliest event reported
  • 001-39385 (company) — Commission File Number
  • 399 Binney Street, Cambridge, Massachusetts 02142 (location) — Address of Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing by Relay Therapeutics, Inc.?

The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on January 13, 2025.

What is Relay Therapeutics, Inc.'s Commission File Number?

Relay Therapeutics, Inc.'s Commission File Number is 001-39385.

Where are Relay Therapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 399 Binney Street, Cambridge, Massachusetts 02142.

What is the IRS Employer Identification Number for Relay Therapeutics, Inc.?

The IRS Employer Identification Number for Relay Therapeutics, Inc. is 47-3923475.

Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-01-13 08:30:15

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share RLAY Nasdaq Global Market

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Relay Therapeutics, Inc. (the "Company") will be conducting meetings with participants attending the 43rd Annual J.P. Morgan Healthcare Conference (the "Conference") during the week of January 13, 2025. A copy of the slides to be presented by the Company at the Conference is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. 99.1 43rd Annual J.P. Morgan Healthcare Conference Company Presentation, dated January 2025, furnished herewith. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RELAY THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ Brian Adams Brian Adams Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.